TRVI - Trevi Therapeutics GAAP EPS of -$0.24 beats by $0.04
Trevi Therapeutics press release (NASDAQ:TRVI): Q1 GAAP EPS of -$0.24 beats by $0.04. As of March 31, 2022, the Company had total cash and cash equivalents of $29.1 million.
For further details see:
Trevi Therapeutics GAAP EPS of -$0.24 beats by $0.04